An Overview of Treat-To-Target in Psoriasis

Experts discuss how psoriasis treatment targets have dramatically evolved. Historically, a 50-75% skin improvement (PASI 50/75) was the benchmark for success. With modern systemic therapies, including advanced biologics targeting IL-17, IL-23, and oral agents, the goal is now near or complete 100% skin clearance. The panel emphasizes that early and aggressive intervention with systemic treatment is key to changing the disease course and achieving sustained remission. This "treat-to-target" mindset aligns with higher patient expectations and recognizes psoriasis as a systemic condition requiring internal therapy. Clearing the skin externally signifies reduced internal inflammation, fundamentally redefining psoriasis treatment success towards achieving clear skin and improved long-term patient quality of life.